×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCAB – bioatla, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/2
04:54 am
bcab
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
High
Report
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
12/31
09:22 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
12/31
07:00 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
11/21
12:25 am
bcab
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
High
Report
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
11/14
07:08 pm
bcab
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
High
Report
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
11/13
06:54 pm
bcab
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
High
Report
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
11/13
06:52 pm
bcab
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/7
09:00 am
bcab
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Low
Report
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/31
07:15 am
bcab
Form 8-K BioAtla, Inc. For: Dec 30
High
Report
Form 8-K BioAtla, Inc. For: Dec 30
12/30
04:06 pm
bcab
Form 8-K BioAtla, Inc. For: Dec 30
High
Report
Form 8-K BioAtla, Inc. For: Dec 30
12/5
04:05 pm
bcab
Form DEF 14A BioAtla, Inc. For: Dec 05
Low
Report
Form DEF 14A BioAtla, Inc. For: Dec 05
12/1
06:37 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: WALDRON RICHARD A
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: WALDRON RICHARD A
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: SHORT JAY M PHD
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: SHORT JAY M PHD
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Vasquez Christian
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Vasquez Christian
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Sievers Eric
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Sievers Eric
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: